Scholarlink

Gastrointestinal (GI) dysmotility is a common yet complex symptom in many patients with scleroderma and other rheumatic disease. This chapter provides a comprehensive review of the pharmacological management of GI motility disorders common in patients with systemic sclerosis (SSc), focusing on the different segments of the GI tract. Therapeutic agents covered include cholinergic agonists, prokinetic agents, promotility antibiotics, laxatives, opioid antagonists, among others. While several medications do show promise in improving GI symptoms in SSc patients, their full utility remains incompletely understood. Future research must focus on optimizing existing pharmacological strategies to better target and improve outcomes in patients with scleroderma-related GI dysfunction.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gastrointestinal Drugs in Scleroderma and GI Dysmotility

  • 章节

  • 发表日期：

    2025年

查看全文
  • Dia Shah,
  • Dharma Ayer,
  • Dareen S. Chuy,
  • Shahad Almahmoud,
  • Kainat Akhtar,
  • Jessica Farrell,
  • Micheal Tadros

摘要

Gastrointestinal (GI) dysmotility is a common yet complex symptom in many patients with scleroderma and other rheumatic disease. This chapter provides a comprehensive review of the pharmacological management of GI motility disorders common in patients with systemic sclerosis (SSc), focusing on the different segments of the GI tract. Therapeutic agents covered include cholinergic agonists, prokinetic agents, promotility antibiotics, laxatives, opioid antagonists, among others. While several medications do show promise in improving GI symptoms in SSc patients, their full utility remains incompletely understood. Future research must focus on optimizing existing pharmacological strategies to better target and improve outcomes in patients with scleroderma-related GI dysfunction.